# NavRx

> NavRx is a precision prescribing platform that uses pharmacogenomics, BioVerify medication verification, and predictive intelligence to reduce medication-related costs, improve patient outcomes, and raise quality metrics for Medicare Advantage plans, ACOs, and value-based care organizations. The platform activates retail pharmacy networks as scalable clinical intervention points.

For more detailed information, see [llms-full.txt](https://navrx.health/llms-full.txt) which contains expanded content from every page on the site.

NavRx addresses the $528 billion annual problem of medication mismanagement in healthcare. The platform's proprietary Medication Risk Index (MRI) is an AI-driven risk model that quantifies the clinical and financial risk embedded in every patient's medication regimen into one actionable score. It identifies who needs intervention before an adverse event creates a claim.

## Core Capabilities

- [Homepage](https://navrx.health/): Platform overview, cost-of-mismanagement statistics, flywheel model, and business impact metrics
- [CMS GUIDE Program](https://navrx.health/cms-guide-program): NavRx provides the pharmacy-powered backbone for CMS GUIDE (Guiding an Improved Dementia Experience) programs, delivering automated medication management inside EHRs to reduce high-risk medication use and caregiver burden
- [About NavRx](https://navrx.health/about): Company background, leadership team, and FAQ covering pharmacogenomics, BioVerify, MTM, adverse drug events, STAR ratings, CMS GUIDE, cost savings, and target audience
- [Strategic Partnerships](https://navrx.health/partnerships): NavRx partners with Precision Molecular (pharmacogenomic testing) and ActX (real-world evidence and data integration) to advance precision prescribing at scale
- [Contact](https://navrx.health/contact): Schedule a platform demo or strategic briefing

## Key Products and Services

The MRI (Medication Risk Index) scoring system combines four data layers: claims and outcomes data, adherence patterns across therapeutic classes, polypharmacy complexity (drug-drug interactions, burden scoring, STOPP/START criteria), and pharmacogenomic insights that predict therapy response.

Platform capabilities include population risk stratification, adherence gap detection, quality and RAF integration (STAR, HEDIS, RAF metrics), and longitudinal performance tracking.

NavRx activates 65,000+ retail pharmacies as intervention points. Retail pharmacy is the highest-frequency clinical touchpoint in healthcare, with 12x more patient interactions annually than other care settings and 90% of Americans living within 5 miles of a pharmacy.

## Business Impact

NavRx targets Medicare Advantage plans, ACOs, and risk-based care arrangements. Measured outcomes include reduction in adverse events and avoidable hospitalizations, scaled adherence in critical therapeutic classes, elevated STAR, HEDIS, and quality metrics, strengthened RAF and risk identification accuracy, and $250-500+ in savings per patient annually.

## Leadership Team

- [James Hopper](https://navrx.health/our-team/james-hopper): Founder and CEO
- [Grey Williams](https://navrx.health/our-team/grey-williams): CFO
- [Christine Gilroy, MD](https://navrx.health/our-team/christine-gilroy): Chief Medical Officer
- [Shawn Dalton](https://navrx.health/our-team/shawn-dalton): Chief Science Officer
- [David Depoyster](https://navrx.health/our-team/david-depoyster): Chief Strategy Officer
- [Scott McGlaun](https://navrx.health/our-team/scott-mcglaun): Chief Information Officer
- [Adam Earl](https://navrx.health/our-team/adam-earl): Board Member
- [Jeremy Stuart](https://navrx.health/our-team/jeremy-stuart): Board Member

## Optional

- [Blog](https://navrx.health/blog/): Insights on precision prescribing, medication management, and the future of personalized care